Lilly prevails in Alimta patent challenge

|About: Eli Lilly and Company (LLY)|By:, SA News Editor

The U.S. Court of Appeals for the Federal Circuit has ruled in Eli Lilly's (LLY -0.9%) favor in a dispute with would-be generic competitors regarding a vitamin regimen patent covering lung cancer med Alimta (pemetrexed).

The generic interlopers, Dr. Reddy's Laboratories (RDY +0.2%) and Pfizer's (PFE -1.8%) Hospira, will have to wait until May 2022 to market their versions, assuming the patent is ultimately upheld.

Subscribe for full text news in your inbox